Treatment of stage IIIA non-small cell lung cancer

Lary A. Robinson, Henry Wagner, John C. Ruckdeschel

Research output: Contribution to journalReview article

98 Citations (Scopus)

Abstract

Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky multistation nodal disease. Controversy abounds as to the optimal treatment of the various stage IIIA subsets, which is fueled by a lack of meaningful, large randomized trials. Multimodality therapy of some type appears to be preferable in stage IIIA patients.

Original languageEnglish (US)
Pages (from-to)202S-220S
JournalCHEST
Volume123
Issue number1 SUPPL.
DOIs
StatePublished - Jan 1 2003

Fingerprint

Non-Small Cell Lung Carcinoma
Therapeutics
Lymph Nodes
Neoplasm Metastasis
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Robinson, L. A., Wagner, H., & Ruckdeschel, J. C. (2003). Treatment of stage IIIA non-small cell lung cancer. CHEST, 123(1 SUPPL.), 202S-220S. https://doi.org/10.1378/chest.123.1_suppl.202S
Robinson, Lary A. ; Wagner, Henry ; Ruckdeschel, John C. / Treatment of stage IIIA non-small cell lung cancer. In: CHEST. 2003 ; Vol. 123, No. 1 SUPPL. pp. 202S-220S.
@article{facfa7e4b5b846c084e0c25329641ff3,
title = "Treatment of stage IIIA non-small cell lung cancer",
abstract = "Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky multistation nodal disease. Controversy abounds as to the optimal treatment of the various stage IIIA subsets, which is fueled by a lack of meaningful, large randomized trials. Multimodality therapy of some type appears to be preferable in stage IIIA patients.",
author = "Robinson, {Lary A.} and Henry Wagner and Ruckdeschel, {John C.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1378/chest.123.1_suppl.202S",
language = "English (US)",
volume = "123",
pages = "202S--220S",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1 SUPPL.",

}

Robinson, LA, Wagner, H & Ruckdeschel, JC 2003, 'Treatment of stage IIIA non-small cell lung cancer', CHEST, vol. 123, no. 1 SUPPL., pp. 202S-220S. https://doi.org/10.1378/chest.123.1_suppl.202S

Treatment of stage IIIA non-small cell lung cancer. / Robinson, Lary A.; Wagner, Henry; Ruckdeschel, John C.

In: CHEST, Vol. 123, No. 1 SUPPL., 01.01.2003, p. 202S-220S.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Treatment of stage IIIA non-small cell lung cancer

AU - Robinson, Lary A.

AU - Wagner, Henry

AU - Ruckdeschel, John C.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky multistation nodal disease. Controversy abounds as to the optimal treatment of the various stage IIIA subsets, which is fueled by a lack of meaningful, large randomized trials. Multimodality therapy of some type appears to be preferable in stage IIIA patients.

AB - Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky multistation nodal disease. Controversy abounds as to the optimal treatment of the various stage IIIA subsets, which is fueled by a lack of meaningful, large randomized trials. Multimodality therapy of some type appears to be preferable in stage IIIA patients.

UR - http://www.scopus.com/inward/record.url?scp=0037250502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037250502&partnerID=8YFLogxK

U2 - 10.1378/chest.123.1_suppl.202S

DO - 10.1378/chest.123.1_suppl.202S

M3 - Review article

C2 - 12527580

AN - SCOPUS:0037250502

VL - 123

SP - 202S-220S

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1 SUPPL.

ER -